Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.42 +0.29 (+0.00%) Bitcoin USD
57,627.94 -3,953.20 (-6.42%) CMC Crypto 200
1,238.05 -101.02 (-7.55%)
Rhythm Pharmaceuticals, Inc. (RYTM)
After hours:
| Previous close | 38.82 |
| Open | 38.39 |
| Bid | 39.64 x 100 |
| Ask | 39.90 x 100 |
| Day's range | 37.60 - 41.14 |
| 52-week range | 15.50 - 52.57 |
| Volume | |
| Avg. volume | 570,462 |
| Market cap | 2.424B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.00 |
ZacksEarnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendo
- GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here.
